Clinicians can bill Category 1 CPT Code 75580 for adjunctive use of the artificial intelligence (AI)-powered Cleerly Ischemia software for fractional flow reserve estimates based on coronary computed tomography angiography (CCTA) scans.
A new Category 1 CPT code may enhance reimbursement for the use of adjunctive artificial intelligence (AI)-enabled software to ascertain fractional flow reserve (FFR) estimates in cases of suspected coronary artery disease (CAD).
The Cleerly Ischemia software (Cleerly), which can now be billed with the Category 1 CPT code 75580, allows non-invasive lesion mapping for findings of CAD, according to Cleerly, the develop of the Cleerly Ischemia software.
“The Cleerly Ischemia software provides noninvasive estimates of FFR values that help healthcare professionals make critical decisions in the management of patients with suspected coronary artery disease,” noted James P. Earls, M.D, the chief medical officer of Cleerly. “Cleerly Ischemia was purposely designed to output estimates of FFR values that are guideline-recommended by professional societies, and to allow comprehensive mapping of both anatomic and physiologic data for each and every coronary lesion across the entire vascular tree.”
Cleerly noted the new Category 1 CPT code is an addition to previously established Category III CPT codes for billing of the company’s advanced coronary atherosclerosis analysis.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.